Key facts
- This page summarizes Philippe Busque's Form 3 filing for Cytek Biosciences, Inc. (CTKB).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 29 Aug 2023, 18:01.
Philippe Busque - 28 Aug 2023 Form 3 Insider Report for Cytek Biosciences, Inc. (CTKB)
- Reporting relationship
- SVP, Global Sales and Services
- Issuer ticker
- CTKB
- Reported as of
- 28 Aug 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 29 Aug 2023, 18:01:44 UTC
- Next SEC filing
- 08 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Valerie Barnett, Attorney-in-Fact for Philippe Busque
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Philippe Busque filed Form 3 for Cytek Biosciences, Inc. (CTKB) on 29 Aug 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTKB
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 28 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,590
- Exercise price
- Footnotes
- F1, F2
CTKB
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 28 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,464
- Exercise price
- Footnotes
- F2, F3
CTKB
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 28 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,562
- Exercise price
- $9.15
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The shares subject to the Restricted Stock Units (the "RSU Award") shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter.
Footnote F2
Each RSU Award represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
The shares subject to the RSU Award shall vest on March 20, 2024.
Footnote F4
The shares subject to the option vest as follows: 25% of the shares subject to the option vests on March 20, 2024; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years.